TTRX: Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
Stocks in this Quantisnow insightHealth Care
Historical context for TTRX
Across the 10 sessions after earlier TTRX headlines, the stock closed higher 3 times and lower 7 times, with a median move of 6.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TTRX | SPY |
|---|---|---|---|
| Jan 12, 2026 | Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference | -8.4% | +0.2% |
| Jan 8, 2026 | Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors | +1.8% | -0.0% |
| Dec 29, 2025 | D. Boral Capital initiated coverage on Turn Therapeutics with a new price target | +14.6% | -0.4% |
| Nov 13, 2025 | Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | -7.0% | -1.7% |
| Nov 12, 2025 | Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D. | +13.4% | +0.1% |
| Nov 11, 2025 | Turn Therapeutics' GX-03 Technology Named as One of "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine | -6.1% | +0.2% |
Quantisnow market dataNASDAQ
TTRX
Turn Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for TTRX
Full TTRX profile on Quantisnow Follow TTRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time